2023
Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments
Krystal J, Kaye A, Jefferson S, Girgenti M, Wilkinson S, Sanacora G, Esterlis I. Ketamine and the neurobiology of depression: Toward next-generation rapid-acting antidepressant treatments. Proceedings Of The National Academy Of Sciences Of The United States Of America 2023, 120: e2305772120. PMID: 38011560, PMCID: PMC10710048, DOI: 10.1073/pnas.2305772120.Peer-Reviewed Original Research
2007
Neurobiology and Treatment of Depression
Neumeister A, Charney D, Sanacora G, Krystal J. Neurobiology and Treatment of Depression. 2007 DOI: 10.1002/9780470101001.hcn018.Peer-Reviewed Original ResearchNeurobiology of depressionTreatment of depressionPotential novel treatment approachesNovel treatment approachesEtiology of depressionAvailable treatmentsDepressed patientsNeuroanatomical disruptionsTreatment approachesNeural circuitsAbstract DepressionNovel targetCurrent conceptsDepressionTreatmentNeurobiological systemsNeurobiologyPatientsPathogenesisEtiologyEnvironmental factors
2002
Evidence for GABAergic and Glutamatergic Involvement in the Pathophysiology and Treatment of Depressive Disorders
Sanacora G. Evidence for GABAergic and Glutamatergic Involvement in the Pathophysiology and Treatment of Depressive Disorders. 2002, 739-749. DOI: 10.1002/0470854871.chxviii3.Peer-Reviewed Original ResearchGlutamatergic abnormalitiesGlutamatergic effectsGABAergic abnormalitiesMood stabilizersAnimal modelsGABAergic contributionGABA's roleDepression EvidenceGlutamatergic involvementDepressive disorderAntidepressantsAbnormalitiesNMDAGABAReference evidenceTreatmentNeurobiologyEvidenceEffect evidenceGABAergicPathophysiologyRole